PNU-159682

Research use only, not for human use.

A highly potent metabolite of the anthracycline nemorubicin with outstanding cytotoxicity; a topoisomerase inhibitor and ADCs cytotoxin.

A highly potent metabolite of the anthracycline nemorubicin with outstanding cytotoxicity; a topoisomerase inhibitor and ADCs cytotoxin.

Cell Viability Assay Cell Line:HT-29, A2780, DU145, EM-2, Jurkat and CEM cells Concentration:0-500 nM Incubation Time:Exposed to the PNU-159682 for 1 hour and then cultured in compound-free medium for 72 hours Result:Was 2,360- to 790-fold and 6,420- to 2,100-fold more potent than MMDX and doxorubicin, respectively. Exhibited IC70?values of PNU-159682 are in the subnanomolar range (0.07-0.58 nM) and noticeably lower than that recorded for both MMDX and doxorubicin.

Animal Model:Four- to six-week-old female CD-1 athymic nude mice with MX-1 tumor fragments Dosage:4 μg/kg Administration:Intravenous injection; q7dx3; 40 days Result:Exhibited anti-cancer effects in MX-1 human mammary carcinoma xenografts to PNU-159682.

PNU159682 | PNU 159682

Antibody Drug Conjugates (ADC)

ADC Cytotoxin

ADC Cytotoxin

Cancer

——

202350-68-3

641.6192

C32H35NO13

>98% (HPLC)

10 mM in DMSO

O=C(C1=C(C2=C(C(O)=C1C3)C[C@@](O)(C(CO)=O)C[C@@H]2O[C@@H]4O[C@H]([C@H]5O[C@@H]6[C@@H](OC)OCCN6[C@H]5C4)C)O)C7=C3C=CC=C7OC

5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[(1S,3R,4aS,9S,9aR,10aS)-octahydro-9-methoxy-1-methyl-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl]oxy]-, (8S,10S)-

(-20℃)

With Ice Pack

≥ 2 years